Inclusion Criteria:

- Parts A, B, and C

- Relapsed, locally-advanced or metastatic colorectal or pancreatic cancer,
sqNSCLC, or SCCHN participants who are not candidates for standard therapy.

- All participants must have experienced disease progression on or after their most
recent systemic therapy.

- Colorectal cancer (closed to enrollment): participants must have received prior
therapy with each of following agents, if eligible: a fluoropyrimidine,
oxaliplatin, irinotecan, and/or bevacizumab. Participants should have received no
more than 3 systemic regimens in the metastatic setting.

- sqNSCLC (closed to enrollment): Participants with NSCLC must have predominant
squamous histology. Participants must have received prior therapy with a
platinum-based treatment and a checkpoint inhibitor (CPI), if eligible.
Participants should have received no more than 3 lines of systemic therapy in the
metastatic setting.

- Participants eligible for a tyrosine kinase inhibitor should have received
such therapy. These participants should have received no more than 4 lines
of systemic therapy in the metastatic setting.

- Exocrine pancreatic adenocarcinoma (closed to enrollment): Participants with
exocrine pancreatic adenocarcinoma must have predominant adenocarcinoma
histology. Participants must have received prior therapy with a gemcitabine-based
or 5FU-based regimen, if eligible, and should have received no more than 1
systemic regimen in the unresectable or metastatic setting.

- SCCHN (closed to enrollment): Participants with SCCHN in Part C must have
received prior therapy with a platinum-based regimen and/or a checkpoint
inhibitor (CPI), if eligible, and must have experienced disease progression
following such therapy. Participants should have received no more than 3 systemic
lines of therapy in the recurrent or metastatic setting.

- Part E

- Participants with SCCHN must have experienced disease progression on or after
their most recent systemic therapy. Participants should have received no more
than 1 or 2 systemic lines of therapy in the recurrent/metastatic setting as
specified below. Participants must have received a platinum-based regimen and a
PD-(L)1 inhibitor.

- Parts D, F, and G

- Part D is closed to enrollment. Part F and Part G will enroll only participants
with SCCHN.

- Participants with SCCHN must have received no previous systemic therapy in the
recurrent or metastatic disease setting.

- Part D only

- Participants with NSCLC must have histologically or cytologically documented
squamous cell NSCLC and must have received no previous systemic therapy for
metastatic disease or radiation therapy to the lung that is > 30 Gy within 6
months of the first dose of study treatment.

- PD-L1 biomarker expression as determined by a PD-L1 IHC assay should be
available

- Part F only

- Participants must have CPS ≥1 by local PD-L1 IHC assay to be eligible for
enrollment. Participants must be able to submit a tissue sample for
retrospective PD-L1 testing. Tissue may be fresh biopsy or archival,
collected within 2 years of Cycle 1 Day 1.

- Part G only

- Non-EU eligibility criteria: No CPS requirement for the cohort evaluating
tisotumab vedotin in combination with pembrolizumab and carboplatin.

- EU-specific eligibility criteria: Participants must have a CPS ≥1 by local
PD-L1 IHC assay.

- Participants must be able to submit a tissue sample for retrospective PD-L1
testing. Tissue may be fresh biopsy or archival, collected within 2 years of
Cycle 1 Day 1.

- Baseline measurable disease as measured by RECIST v1. 1.

- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.

Exclusion Criteria:

- Participants with primary neuroendocrine or sarcomatoid histologies. For SCCHN,
participants may not have a primary site of nasopharynx or salivary gland.

- Active bleeding conditions

- Ocular surface disease at the time of enrollment (Note: cataract is not considered
active ocular surface disease for this protocol)

- Other cancer: known past or current malignancy other than inclusion diagnosis.

- Uncontrolled tumor-related pain

- Inflammatory lung disease. Participants with pulmonary disease are allowed if systemic
steroids and long-term oxygen are not required

- Peripheral neuropathy greater than or equal to Grade 2

- Active brain metastasis

- Part D, F, and G Only: Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2
agent or with an agent directed to another stimulatory or co-inhibitory T-cell
receptor.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/30/24. Questions regarding updates should be directed to the study team contact.